Comparative Safety Profiles of Bevacizumab, Ranibizumab and Pegaptanib in the Treatment of Age-Related Macular Degeneration: the Analysis of the WHO Database of Adverse Drug Reactions

被引：0
|
作者：
Biagi, Chiara [1 ]
Conti, Valentino [2 ]
Bonisolli, Marta [1 ]
Melis, Mauro [1 ]
Buccellato, Elena [1 ]
Covezzoli, Anna [3 ]
Amato, Roberta [3 ]
Pazzi, Linda [3 ]
Venegoni, Mauro [2 ]
Vaccheri, Alberto [1 ]
Motola, Domenico [1 ]
机构：
[1] Univ Bologna, Dept Med & Surg Sci, Pharmacol Unit, Bologna, Italy
[2] Reg Ctr Pharmacovigilance, Milan, Lombardy Region, Italy
[3] CINECA, Interuniv Consortium, Hlth Care Syst Dept, Bologna, Italy
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2014年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
522
引用
收藏
页码：276 / 276
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration
    Luis Javier Hernández-Pastor
    Ana Ortega
    Alfredo García-Layana
    Joaquín Giráldez
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248 : 467 - 476
  • [32] Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration
    Landa, Gennady
    Amde, Wendewessen
    Doshi, Vatsal
    Ali, Amro
    McGevna, Laura
    Gentile, Ronald C.
    Muldoon, Thomas O.
    Walsh, Joseph B.
    Rosen, Richard B.
    OPHTHALMOLOGICA, 2009, 223 (06) : 370 - 375
  • [33] RANIBIZUMAB AND BEVACIZUMAB FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION: A SYSTEMATIC REVIEW AND ECONOMIC EVALUATION
    Martinez Ferez, I. M.
    Flores Moreno, S.
    VALUE IN HEALTH, 2011, 14 (07) : A503 - A504
  • [34] Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration
    Desideri, Lorenzo Ferro
    Barra, Fabio
    Ferrero, Simone
    Traverso, Carlo Enrico
    Nicolo, Massimo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (08) : 735 - 751
  • [35] BEVACIZUMAB VERSUS RANIBIZUMAB FOR AGE-RELATED MACULAR DEGENERATION (AMD): A BUDGET IMPACT ANALYSIS
    Zimmermann, I
    Schneiders, R. E.
    Mosca, M.
    Alexandre, R. F.
    do Nascimento Jr, J. M.
    Gadelha, C. A.
    VALUE IN HEALTH, 2012, 15 (07) : A569 - A569
  • [36] Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a Meta-analysis
    Wang, Wen-Jie
    Chen, Jian
    Zhang, Xiao-Ling
    Yao, Min
    Liu, Xiao-Yong
    Zhou, Qing
    Qu, Yi-Xin
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2015, 8 (01) : 138 - 147
  • [37] Comparative effects of Bevacizumab and Ranibizumab on endothelial cells. Implications in age-related macular degeneration
    Costa, Raquel
    Pirraco, Ana
    Falcao, Manuel
    Carneiro, Angela
    Rocha, Ana
    Soares, Raquel
    FASEB JOURNAL, 2009, 23
  • [38] Treatment of age-related macular degeneration: focus on ranibizumab
    Spitzer, Martin S.
    Ziemssen, Focke
    Bartz-Schmidt, Karl U.
    Gelisken, Faik
    Szurman, Peter
    CLINICAL OPHTHALMOLOGY, 2008, 2 (01): : 1 - 14
  • [39] Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration
    Chen, Youxin
    Han, Fei
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2012, 8 : 343 - 351
  • [40] Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration
    Sivaprasad, Sobha
    CLINICAL OPHTHALMOLOGY, 2008, 2 (02): : 339 - 346
12345